Christiane Neumann

This inventor holds 12 USPTO granted patents and 26 published patent applications and 8 EPO patents. Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, Roche Glyeart Ag. Active years: 2018-2024.

USPTO Granted Patents = 12 (Patent Applications = 26)

% Patents Active = 91.7

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 39(Granted Patents)

Location History:

Niederweningen, CH (2018 - 2022)
Wallisellen, CH (2023)

Company Filing History:

6 out of 5,020

Hoffmann-La Roche Inc.

Years Active: 2018-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12103982 - T cell activating bispecific antigen binding molecules (2024-10-01),

2. 11639397 - Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use (2023-05-02),

3. 11459404 - Bispecific T cell activating antigen binding molecules (2022-10-04),

4. 11117965 - Bispecific T cell activating antigen binding molecules (2021-09-14),

5. 10781258 - Bispecific T cell activating antigen binding molecules (2020-09-22),

6. 10781257 - Bispecific T cell activating antigen binding molecules (2020-09-22),

7. 10766967 - Bispecific T cell activating antigen binding molecules (2020-09-08),

8. 10611841 - Bispecific T cell activating antigen binding molecules (2020-04-07),

9. 10611840 - Bispecific T cell activating antigen binding molecules (2020-04-07),

10. 10323099 - Multispecific domain exchanged common variable light chain antibodies (2019-06-18),

11. 10155815 - Bispecific T cell activating antigen binding molecules (2018-12-18),

12. 10087250 - Fc-free antibodies comprising two fab-fragments and methods of use (2018-10-02),

Title: Christiane Neumann: Innovator in Bispecific Antigen Binding Molecules

Introduction

Christiane Neumann is a prominent inventor based in Niederweningen, Switzerland. She has made significant contributions to the field of biomedicine, particularly in the development of bispecific antigen binding molecules. With a total of 12 patents to her name, her work has the potential to revolutionize treatments for various diseases.

Latest Patents

One of her latest patents focuses on T cell activating bispecific antigen binding molecules. This invention relates to novel bispecific antigen binding molecules designed for T cell activation and re-direction to specific target cells. It includes polynucleotides encoding these molecules, as well as methods for their production and use in disease treatment. Another significant patent involves bispecific antibodies that bind both a T-cell activating antigen and a tumor antigen. This invention comprises a first Fab fragment and a second Fab fragment, with specific modifications to enhance efficacy.

Career Highlights

Christiane Neumann has worked with notable companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Roche Glycart AG. Her experience in these organizations has allowed her to develop and refine her innovative ideas in the field of biomedicine.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues such as Christian Klein and Pablo Umana. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Christiane Neumann is a trailblazer in the development of bispecific antigen binding molecules, with a strong patent portfolio and a career marked by significant collaborations. Her work continues to impact the field of biomedicine and offers promising avenues for future research and treatment options.